Inizia
AlenCiken

$PRQR Announces Positive Results from Clinical Trial of QR-421a

ProQR Therapeutics N.V. (NASDAQ:PRQR)  
AlenCiken Aggiornato   
NASDAQ:PRQR   ProQR Therapeutics N.V.
Trend Analysis Chart Patterns Fundamental Analysis biotech biotechnology biotechstocks biotechs biotechstock biotehnology
1
0
trendanalysis chartpattern fundamental biotech biotechnology biotechstocks biotechs biotechstock biotehnology
ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials.

QR-421a demonstrated a concordant benefit in multiple measures of vision, including best corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT)

QR-421a observed to be well tolerated with no serious adverse events reported

Two pivotal Phase 2/3 trials are expected to start by the end of 2021

finance.yahoo.com/ne...nical-110000726.html
Commento:
Citigroup Reiterated buy $33 → $44
Declinazione di responsabilità

Le informazioni ed i contenuti pubblicati non costituiscono in alcun modo una sollecitazione ad investire o ad operare nei mercati finanziari. Non sono inoltre fornite o supportate da TradingView. Maggiori dettagli nelle Condizioni d'uso.